GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Is it possible altering the fucose may increase the affinity of antibody for the target cell?<

To my knowledge, no company is touting a fucosylation-related benefit in a mAb’s affinity for its binding site, so the answer to your is presumably No.


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”